Skip to content

Electromagnetic transduction therapy in low back pain: a prospective randomised controlled trial

Electromagnetic transduction therapy in low back pain: a prospective randomised controlled trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
DRKS
Registry ID
DRKS00011648
Enrollment
88
Registered
2017-02-02
Start date
2016-02-15
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M54.5

Interventions

Group 1: 44 patients with non-specific low back pain treated with physiotherapy including core stabilisation, isometric strengthening and physical therapy plus non-opiate analgesics (Ibuprofen 2x800mg
3 Hz
30kV, 20min each time)

Sponsors

Klinik für Orthopädie und Unfallchirurgie, Universitätsklinikum Schleswig Holstein, Campus Kiel, Deutschland
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Non-specific low back pain; At least 3 weeks duration of symptoms; NSAIDs treatment washout period of 1 weeks; VAS pain score > 3; Age greater than 18 years

Exclusion criteria

Exclusion criteria: Radicular pain or serious spinal pathology; Previous spinal surgery intervention; Spinal infection Spinal metastasis or malignant tumor; Spondylolisthesis; Violent trauma; VAS Pain score < 4; Significant coagulation disturbance; NSAIDs hypersensitivity

Design outcomes

Primary

MeasureTime frame
Primary endpoints were at least 60 % reduction of pain in 10-point visual analogue scale (VAS) from baseline to 12 weeks' follow-up. The change in pain sensation was defined as change of back pain while doing daily activities. The pressure level that just elicited unbearable pain was related to a VAS score 10.

Secondary

MeasureTime frame
Secondary endpoints were single changes in visual analogue scale scores (VAS) and Oswestry Disability Index Score (ODS) (0 – 100% disability; minimal disability (=0%) to either bed-bound or exaggerating symptoms (=100%1) 6 and 12 weeks after last interventions.

Countries

Germany

Contacts

Public ContactLudger Gerdesmeyer

Klinik für Orthopädie und Unfallchirurgie, Universitätsklinikum Schleswig Holstein, Campus Kiel, Deutschland

gerdesmeyer@aol.com043150024485

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026